Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022.
News
Article
Scientific Papers
Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents
The efficacy of the BNT162b2 vaccine in pediatrics was assessed by randomised trials before the Omicron variant’s emergence.
Evaluation of the effectiveness and impact of Nirsevimab in Galicia
The NIRSE-GAL study shows in real time the evolution of the coverage achieved by immunisation with Nirsevimab in children and compares RSV admissions in different population groups of children and adults in Galicia in Spain with previous years.
First results in using new tools to tackle respiratory syncytial virus
Protecting infants from RSV with new tools: vaccines for pregnant women and use of monoclonal antibodies have been approved for use in the European Union to prevent RSV among young children. Are those tools working?
RSV IMMUNISATION FOR INFANTS IN EUROPE: ARE OUR HEALTH SYSTEMS READY?
EHMA publishes a paper based on expert insight from across Europe, exploring the challenges and opportunities of implementing RSV immunisation programmes in different country contexts.
Risk factors for severe respiratory syncytial virus infection during the first year of life: development and validation of a clinical prediction model
Novel immunisation methods against respiratory syncytial virus (RSV) are emerging, but knowledge of risk factors for severe RSV disease is insufficient for optimal targeting of interventions against them.
Risk factors for severe respiratory syncytial virus infection during the first year of life: development and validation of a clinical prediction model
Novel immunisation methods against respiratory syncytial virus (RSV) are emerging, but knowledge of risk factors for severe RSV disease is insufficient for optimal targeting of interventions against them.
mRNA SARS-CoV-2 Vaccination Before vs During Pregnancy and Omicron Infection Among Infants
Infants younger than 6 months are at risk of severe SARS-CoV-2 infection.
Why Vaccinate Healthy 2- to 17-Year-Olds Against Influenza?
On February 2023, the French National Authority for Health (HAS) recommended extending flu shots to children aged 2-17 years without comorbidities.
Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan
CD8+ T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear.
International Pediatric COVID-19 Severity Over the Course of the Pandemic
This cohort study suggested that while intensive care unit admission decreased over the course of the pandemic in all age groups, ventilatory and oxygen support did not decrease over time in children aged younger than 5 years.
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Nirsevimab is a monoclonal antibody that binds to the RSV fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season.
